Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels

@article{Bhosale2010ClinicalUO,
  title={Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels},
  author={Priya Bhosale and Silanath Peungjesada and Wei Wei and Charles F. Levenback and Kathleen M. Schmeler and Eric Rohren and Homer Macapinlac and Revathy B. Iyer},
  journal={International Journal of Gynecologic Cancer},
  year={2010},
  volume={20},
  pages={936 - 944}
}
Objectives: This study was conducted to estimate the accuracy of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as compared with contrast-enhanced CT (CECT) in detecting cancer in patients who have normal cancer antigen (CA)-125 (<35 U/dL) but are suspected of having a recurrent disease based on clinical symptoms. Methods: We retrospectively reviewed the records of patients who had undergone primary cytoreductive surgery and subsequently underwent CECT… Expand
View on BMJ
ncbi.nlm.nih.gov
56 Citations
Highly Influential Citations
2
Background Citations
11
Methods Citations
5
Results Citations
1

56 Citations

Citation Type

Citation Type

Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma
TLDR
FDG PET/CT has a high sensitivity for pancreatic cancer recurrence and is useful when CECT is equivocal and can detect recurrence in patients with normal levels of CA 19-9. Expand
Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.
TLDR
Metabolic imaging with FDG PET/CT proved useful in patients where OC recurrence was suspected, even when the value of tumor marker CA125 was in a normal range, and showed that only age and peritoneum recurrence as determined by PET were identified as independent predictors of poor prognosis. Expand
Diagnostic value of integrated 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients
TLDR
Compared with CECT, 18F-FDG-PET/CT shows higher sensitivity in lesion-based analysis and better accuracy of patient selection for secondary cytoreduction in suspected recurrence of epithelial ovarian cancer with non-disseminated lesions. Expand
Role of 18F-FDG PET/CT in the detection of ovarian cancer recurrence in the setting of normal tumor markers
TLDR
Combined 18F-FDG PET/CT with contrast enhancement is more accurate than CE-CT alone in the diagnosis of ovarian tumor recurrence in patients with normal tumor markers. Expand
Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study
TLDR
18F-FDG PET/CT appears to be the more reliable imaging technique for the evaluation of patients with suspicious recurrent ovarian cancer, and for the selection of those more suitable for secondary cytoreductive surgery. Expand
Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up
TLDR
On account of its impact on treatment planning, and especially in predicting patient outcome, FDG PET is a valuable diagnostic tool for cases of suspected ovarian cancer recurrence. Expand
Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas: Correlation With Histology, Serum CA-125 Assay, and Conventional Radiological Modalities
TLDR
FDG PET/CT was proven to be more efficient than serum CA-125 assay and CI in detecting recurrences of ovarian cancer after treatment and should be considered a useful diagnostic tool in the surveillance of patients that received treatment for epithelial ovarian carcinoma. Expand
Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center
TLDR
PET/CT has been proven to be extremely valuable in the evaluation of patients with recurrent ovarian cancer and is particularly helpful in guiding treatment planning. Expand
Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy
TLDR
Combined18F-FDG PET/Ce-CT significantly outperforms Ce-CT alone in the post-treatment detection of malignant ovarian tumors. Expand
Accuracy of Positron Emission Tomography/Computed Tomography in the Diagnosis and Restaging for Recurrent Ovarian Cancer: A Meta-Analysis
TLDR
Positron emission tomography/computed tomography is a useful tool for predicting the diagnosis and restaging of suspected recurrent ovarian carcinoma. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings
  • H. Chung, W. Kang, +5 authors H. Lee
  • Medicine
  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2006
TLDR
Integrated FDG PET/CT is a sensitive post-therapy surveillance modality for the detection of recurrent ovarian cancer; it aids decisions on treatment plans and may ultimately have a favourable impact on prognosis. Expand
Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
TLDR
FDG-PET/CT has the greatest utility in settings of suspected ovarian cancer recurrence, particularly in patients with rising CA-125 levels and negative conventional imaging. Expand
[F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
TLDR
Preliminary results suggest that in the follow-up of patients with ovarian cancer FDG-PET could detect recurrence with higher accuracy than CT, and even with higher sensitivity than the tumor marker CA125, being useful at the same time to locate the recurrence when the tumor markers is positive. Expand
Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
TLDR
Positron emission tomography/computed tomography introduction in this population is cost-effective and allowed to redirect the clinical management of patients towards more appropriate therapeutic choices. Expand
Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review.
TLDR
The preliminary findings suggest that combined PET/CT may be an effective means of identifying patients with recurrent ovarian/fallopian tube cancer and could potentially proceed to salvage treatment and avoid the morbidity and expense of surgical assessment. Expand
Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
TLDR
No statistically significant difference was observed for the investigated imaging modalities with regard to lesion characterization or detection of recurrent disease; thus, the methods are permissible alternatives. Expand
[Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
TLDR
PET-CT could reveal recurrence and (or) metastasis which may be missed or could not be confirmed by routine diagnostic methods before clinical presentations, and combined with the continual detection of CA125, a high accuracy of diagnosis can be achieved. Expand
Influence of 2-(18F) Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography on Recurrent Ovarian Cancer Diagnosis and on Selection of Patients for Secondary Cytoreductive Surgery
TLDR
The diagnostic value of PET/CT for detecting recurrent OC was higher than those of US and CT and that PET/ CT more accurately identified patients with solitary recurrence. Expand
2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
TLDR
FDG PET provides the chance to detect recurrent ovarian cancer at an earlier stage during follow-up as well as preceded the conventional diagnosis by a median of 6 months in patients judged clinically free of disease. Expand
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
  • B. Hillner, B. Siegel, +5 authors R. Coleman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
This large, prospective, nationally representative registry of elderly cancer patients found that physicians often change their intended management on the basis of PET scan results across the full spectrum of its potential uses. Expand
...
1
2
3
4
5
...